A new platelet cryoprecipitate glue promoting bone formation after ectopic mesenchymal stromal cell-loaded biomaterial implantation in nude mice
1 Department of Research, ≪Centre de Transfusion Sanguine des Armées Jean Julliard≫, 1 rue Lieutenant Raoul Batany, Clamart, 92141, France
2 Celogos, 15 rue Beranger, Paris, 75003, France
3 UMR8081-IRCIV, Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif 94805, France
4 Service Anatomie-Pathologie, Hôpital Percy, 101 avenue Henri Barbusse, Clamart, 92141, France
5 Département de Physiologie Aérospatiale, Institut de Recherche Biomédicale des Armées, Brétigny sur orge, 91223, France
6 Ecole du Val de Grâce, 1 Place Alphonse Laveran, Paris, 75005, France
Stem Cell Research & Therapy 2013, 4:1 doi:10.1186/scrt149Published: 4 January 2013
This study investigated the promising effect of a new Platelet Glue obtained from Cryoprecipitation of Apheresis Platelet products (PGCAP) used in combination with Mesenchymal Stromal Cells (MSC) loaded on ceramic biomaterials to provide novel strategies enhancing bone repair.
PGCAP growth factor content was analyzed by ELISA and compared to other platelet and plasma-derived products. MSC loaded on biomaterials (65% hydroxyapatite/35% beta-TCP or 100% beta-TCP) were embedded in PGCAP and grown in presence or not of osteogenic induction medium for 21 days. Biomaterials were then implanted subcutaneously in immunodeficient mice for 28 days. Effect of PGCAP on MSC was evaluated in vitro by proliferation and osteoblastic gene expression analysis and in vivo by histology and immunohistochemistry.
We showed that PGCAP, compared to other platelet-derived products, allowed concentrating large amount of growth factors and cytokines which promoted MSC and osteoprogenitor proliferation. Next, we found that PGCAP improves the proliferation of MSC and osteogenic-induced MSC. Furthermore, we demonstrated that PGCAP up-regulates the mRNA expression of osteogenic markers (Collagen type I, Osteonectin, Osteopontin and Runx2). In vivo, type I collagen expressed in ectopic bone-like tissue was highly enhanced in biomaterials embedded in PGCAP in the absence of osteogenic pre-induction. Better results were obtained with 65% hydroxyapatite/35% beta-TCP biomaterials as compared to 100% beta-TCP.
We have demonstrated that PGCAP is able to enhance in vitro MSC proliferation, osteoblastic differentiation and in vivo bone formation in the absence of osteogenic pre-induction. This clinically adaptable platelet glue could be of interest for improving bone repair.